| Combination of | |
|---|---|
| Morphine sulfate | Opioid |
| Naltrexone | Opioid antagonist |
| Clinical data | |
| Trade names | Embeda |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| (verify) | |
Morphine/naltrexone, sold under the brand nameEmbeda, is anopioid combination pain medication developed byKing Pharmaceuticals for use in moderate to severe pain.[2] The active ingredients aremorphine sulfate andnaltrexone hydrochloride; morphine being anopioid receptor agonist andnaltrexone anopioid receptor antagonist. It is aSchedule II controlled substance in the United States and is intended for long-term pain caused by malignancy or where lower tiers of thepain management ladder have already been exhausted, and where medications such asoxycodone would otherwise have been indicated.[1]
King Pharmaceuticals temporarily recalled Embeda in 2011 after complaints from the US Food and Drug Asministration (FDA) in regard to King Pharmaceuticals omitting information regarding the potentially fatal reaction if crushed and swallowed and also for making unsubstantiated claims regarding Embeda's reduced abuse potential.[3]
